Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Shire PLC (NASDAQ:SHPG)

194.82
Delayed Data
As of 3:59pm ET
 -4.75 / -2.38%
Today’s Change
147.60
Today|||52-Week Range
231.32
-4.97%
Year-to-Date
Third Value Fund Avenue Buys 3 Stocks in 3rd Quarter
Sep 28 / GuruFocus News - Paid Partner Content
Mairs and Power Buys Walt Disney, Exits Baxalta
Sep 27 / GuruFocus News - Paid Partner Content
Momenta to Regain Rights to Humira Biosimilar from Shire
Sep 28 / Zacks.com - Paid Partner Content
Shire's Immunodeficiency Treatment Cuvitru Gets FDA Approval
Sep 15 / Zacks.com - Paid Partner Content
Whitman's Third Avenue Buys 3 Pharma Stocks in 3rd Quarter
Sep 27 / GuruFocus News - Paid Partner Content
 

Today’s Trading

Previous close199.57
Today’s open199.75
Day’s range193.79 - 200.11
Volume801,303
Average volume (3 months)1,966,830
Market cap$60.0B
Dividend yield0.41%
Data as of 3:59pm ET, 09/29/2016

Growth & Valuation

Earnings growth (last year)-61.89%
Earnings growth (this year)+10.34%
Earnings growth (next 5 years)+13.91%
Revenue growth (last year)+6.79%
P/E ratio31.6
Price/Sales6.33
Price/Book4.00

Competitors

 Today’s
change
Today’s
% change
ABTAbbott Laboratories-0.85-2.01%
REGNRegeneron Pharmaceut...-12.74-3.04%
CELGCelgene-3.06-2.89%
AZNAstraZeneca-0.77-2.28%
Data as of 4:03pm ET, 09/29/2016

Financials

Next reporting dateOctober 28, 2016
EPS forecast (this quarter)$3.25
Annual revenue (last year)$6.4B
Annual profit (last year)$1.3B
Net profit margin20.84%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chief Executive Officer &
Executive Director
Flemming Ornskov
Chief Financial Officer &
Executive Director
Jeffrey Poulton
Corporate headquarters
Dublin, Dublin

Forecasts

Search for Jobs